spironolactone has been researched along with Primary Hyperparathyroidism in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a pre-specified analysis of the "Eplerenone in primary hyperparathyroidism" placebo-controlled, randomized trial (ISRCTN 33941607), effects of eight weeks MR-blockade with eplerenone on bone turnover markers in 97 patients with primary hyperparathyroidism were tested." | 9.24 | Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial. ( Alesutan, I; Amrein, K; Brussee, H; Catena, C; Dimai, HP; Fahrleitner-Pammer, A; Grübler, MR; März, W; Meinitzer, A; Pilz, S; Schwetz, V; Tomaschitz, A; Trummer, C; Verheyen, N; Voelkl, J; von Lewinski, D, 2017) |
| "The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial." | 9.22 | Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial. ( Aberer, F; Alesutan, I; Belyavskiy, E; Brussee, H; Dimai, HP; Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Haas, J; Hartaigh, BÓ; Horina, JH; Lang, F; März, W; Meinitzer, A; Ofner-Ziegenfuss, L; Pieske, B; Pieske-Kraigher, E; Pilz, S; Ritz, E; Rus-Machan, J; Schwetz, V; Stiegler, C; Tomaschitz, A; Verheyen, N; Verheyen, S; Voelkl, J, 2016) |
| "Cross-sectional data of the single-center "Eplerenone in Primary Hyperparathyroidism" trial were used." | 7.83 | Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. ( Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J, 2016) |
| " In a pre-specified analysis of the "Eplerenone in primary hyperparathyroidism" placebo-controlled, randomized trial (ISRCTN 33941607), effects of eight weeks MR-blockade with eplerenone on bone turnover markers in 97 patients with primary hyperparathyroidism were tested." | 5.24 | Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial. ( Alesutan, I; Amrein, K; Brussee, H; Catena, C; Dimai, HP; Fahrleitner-Pammer, A; Grübler, MR; März, W; Meinitzer, A; Pilz, S; Schwetz, V; Tomaschitz, A; Trummer, C; Verheyen, N; Voelkl, J; von Lewinski, D, 2017) |
| "The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial." | 5.22 | Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial. ( Aberer, F; Alesutan, I; Belyavskiy, E; Brussee, H; Dimai, HP; Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Haas, J; Hartaigh, BÓ; Horina, JH; Lang, F; März, W; Meinitzer, A; Ofner-Ziegenfuss, L; Pieske, B; Pieske-Kraigher, E; Pilz, S; Ritz, E; Rus-Machan, J; Schwetz, V; Stiegler, C; Tomaschitz, A; Verheyen, N; Verheyen, S; Voelkl, J, 2016) |
| " The recent introduction of a novel, long-acting testosterone formulation (testosterone undecanoate) which only requires one intramuscular injection every 3 months, together with the already available hydroalcoholic testosterone gels, appear to be promising alternatives to the previous standard substitution therapy for male hypogonadism." | 4.83 | [The latest developments in endocrinology 2004/2005]. ( Fottner, C; Weber, MM, 2006) |
| "Cross-sectional data of the single-center "Eplerenone in Primary Hyperparathyroidism" trial were used." | 3.83 | Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial. ( Belyavskiy, E; Brandenburg, VM; Brussee, H; Catena, C; Fahrleitner-Pammer, A; Gaksch, M; Grübler, MR; März, W; Meinitzer, A; Perl, S; Pieske, B; Pilz, S; Scharnagl, H; Sechi, LA; Tomaschitz, A; Van Ballegooijen, AJ; Verheyen, N; Wetzel, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verheyen, N | 3 |
| Grübler, MR | 2 |
| Meinitzer, A | 3 |
| Trummer, C | 1 |
| Schwetz, V | 2 |
| Amrein, K | 1 |
| Dimai, HP | 2 |
| März, W | 3 |
| Catena, C | 2 |
| von Lewinski, D | 1 |
| Voelkl, J | 2 |
| Alesutan, I | 2 |
| Fahrleitner-Pammer, A | 3 |
| Brussee, H | 3 |
| Pilz, S | 3 |
| Tomaschitz, A | 3 |
| DeCarlo, KE | 1 |
| Agrawal, N | 1 |
| Petramala, L | 1 |
| Savoriti, C | 1 |
| Zinnamosca, L | 1 |
| Marinelli, C | 1 |
| Settevendemmie, A | 1 |
| Calvieri, C | 1 |
| Catani, M | 1 |
| Letizia, C | 1 |
| Pieske, B | 2 |
| Belyavskiy, E | 2 |
| Haas, J | 1 |
| Pieske-Kraigher, E | 1 |
| Verheyen, S | 1 |
| Ofner-Ziegenfuss, L | 1 |
| Hartaigh, BÓ | 1 |
| Aberer, F | 1 |
| Grübler, M | 1 |
| Lang, F | 1 |
| Gaksch, M | 2 |
| Horina, JH | 1 |
| Rus-Machan, J | 1 |
| Stiegler, C | 1 |
| Ritz, E | 1 |
| Wetzel, J | 1 |
| Sechi, LA | 1 |
| Van Ballegooijen, AJ | 1 |
| Brandenburg, VM | 1 |
| Scharnagl, H | 1 |
| Perl, S | 1 |
| Fottner, C | 1 |
| Weber, MM | 1 |
1 review available for spironolactone and Primary Hyperparathyroidism
| Article | Year |
|---|---|
[The latest developments in endocrinology 2004/2005].
Topics: Adrenal Gland Neoplasms; Adult; Bone Density Conservation Agents; Chronic Kidney Disease-Mineral and | 2006 |
2 trials available for spironolactone and Primary Hyperparathyroidism
| Article | Year |
|---|---|
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Topics: Aged; Biomarkers; Bone Remodeling; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Humans; Hy | 2017 |
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Double-Blind Method; Echocard | 2016 |
3 other studies available for spironolactone and Primary Hyperparathyroidism
| Article | Year |
|---|---|
Double hit! A unique case of resistant hypertension.
Topics: Adrenal Glands; Aldosterone; Diuretics; Female; Humans; Hyperaldosteronism; Hyperparathyroidism, Pri | 2017 |
Primary aldosteronism with concurrent primary hyperparathyroidism in a patient with arrhythmic disorders.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Arrhythmias, Cardiac; Electr | 2013 |
Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
Topics: Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2016 |